Fig. 1
Three-year OS between lenvatinib plus pembrolizumab and re-challenge PT after propensity score matching. OS, overall survival
Fig. 1 | BMC Medicine
Three-year OS between lenvatinib plus pembrolizumab and re-challenge PT after propensity score matching. OS, overall survival